LYEL — Lyell Immunopharma, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1806952 ·
Last close
$13.67
Market Cap
$336.08M
52W High
$45.00
52W Low
$7.20
ADV30
229,490
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 3,000 — -48,295,000 -45,529,000 273,854,000 92,053,000 81,133,000
Jun 2026 4,000 — -47,337,000 -44,755,000 311,153,000 72,985,000 77,338,000
Mar 2026 2,000 — -44,261,000 -24,153,000 350,626,000 90,770,000 76,961,000
Dec 2025 6,000 — -61,312,000 -140,723,000 340,052,000 60,181,000 91,850,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-139,250,000
Investing CF
$55,223,000
Financing CF
$52,507,000
CapEx
$-715,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-11.50
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,733,991,000
Inventory
—
Receivables
—
ST Investments
$85,053,000
EBIT TTM
$-201,205,000
Pretax Income TTM
$-255,160,000
Interest Exp TTM
—
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$15,000
EBITDA
$-192,248,992
Free Cash Flow
$-65,903,752
Enterprise Value
$232,520,496
Total Cash
$177,106,000
Total Debt
$44,285,000
Shares Out
24,585,565
Trailing EPS
$-12.61
Book Value
$7.84
ROE
-97.8%
ROA
-36.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 36,000 -201,629,000 -274,448,000 340,052,000 91,850,000 248,202,000 -150,024,000
Dec 2024 61,000 -220,274,000 -342,994,000 490,859,000 108,035,000 382,824,000 -162,394,000
Dec 2023 130,000 -247,008,000 -234,632,000 750,029,000 95,077,000 654,952,000 -163,694,000
Dec 2022 84,683,000 -187,058,000 -183,118,000 937,561,000 104,309,000 833,252,000 -169,555,000

TTM Snapshot

Revenues TTM
$27,000
NetIncome TTM
$-248,477,000
OpCashFlow TTM
—
Assets (Latest)
$311,153,000
Forward EPS
$-6.32

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $16.00 · spot: $13.89 · call volume: 191 · put volume: 35
Expected Move to 2027-01-15: ±$4.16 (29.95%) — implied range $9.73 – $18.05 · ATM straddle on $14.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CTNM Contineum Therapeutics, Inc. $337.62M $9.55 —
VREOF Vireo Growth Inc. $346.76M $6.01 —
ASPE Aspen Neuroscience, Inc. $348.94M $12.00 —
RLMD RELMADA THERAPEUTICS, INC. $321.15M $3.01 —
AVIR Atea Pharmaceuticals, Inc. $318.00M $3.96 —

News headlines (Yahoo Finance, 1h cache)

Wall Street Analysts See a 148.25% Upside in Lyell Immunopharma (LYEL): Can the Stock Really Move This High?
2026-11-16 13:55 · Yahoo
Lyell Immunopharma Targets Mid-2027 Pivotal Data for Lymphoma CAR-T Therapy
2026-11-06 08:14 · Yahoo
Lyell Immunopharma: Q3 Earnings Snapshot
2026-11-04 22:24 · Yahoo
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
2026-11-04 21:05 · Yahoo
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
2026-11-04 14:02 · Yahoo
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory L
2026-11-04 14:01 · Yahoo
Lyell Immunopharma To Participate in November Investor Events
2026-11-02 13:00 · Yahoo
Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
2026-10-13 12:35 · Yahoo
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
2026-09-10 20:05 · Yahoo
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet
2026-07-02 13:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.